Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Samantha V WilkinsonElizabeth WilliamsonAna PokrajacDamian FogartyHeide Stirnadel-FarrantLiam SmeethIan J DouglasLaurie A TomlinsonPublished in: Diabetes, obesity & metabolism (2020)
In routine care, SGLT2 inhibitors had greater effects on cardiometabolic risk factors than SUs. Routine care data closely replicated the effects of diabetes drugs on physiological variables measured in clinical trials.
Keyphrases
- primary care
- clinical trial
- healthcare
- risk factors
- palliative care
- type diabetes
- quality improvement
- clinical practice
- cardiovascular disease
- pain management
- electronic health record
- open label
- randomized controlled trial
- cross sectional
- big data
- metabolic syndrome
- phase ii
- skeletal muscle
- health insurance
- general practice
- double blind